"Apolipoprotein B-100" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 513-kDa protein synthesized in the LIVER. It serves as the major structural protein of low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). It is the ligand for the LDL receptor (RECEPTORS, LDL) that promotes cellular binding and internalization of LDL particles.
| Descriptor ID |
D053299
|
| MeSH Number(s) |
D10.532.091.300.249 D12.776.070.400.300.249 D12.776.521.120.300.249
|
| Concept/Terms |
Apolipoprotein B-100- Apolipoprotein B-100
- Apolipoprotein B 100
- ApoB-100
- ApoB 100
- Apo B-100
- Apo B 100
- Apo-B-100
|
Below are MeSH descriptors whose meaning is more general than "Apolipoprotein B-100".
Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein B-100".
This graph shows the total number of publications written about "Apolipoprotein B-100" by people in this website by year, and whether "Apolipoprotein B-100" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Apolipoprotein B-100" by people in Profiles.
-
Lp(a), oxidized phospholipids and oxidation-specific epitopes are increased in subjects with keloid formation. Lipids Health Dis. 2022 Nov 01; 21(1):113.
-
Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. Arterioscler Thromb Vasc Biol. 2020 11; 40(11):2747-2755.
-
Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. Curr Atheroscler Rep. 2019 11 19; 21(12):48.
-
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
-
The Effects of Mipomersen on Inhibiting Hepatic VLDL Apolipoprotein B100 Synthesis and Propensity for Hepatic Steatosis. Clin Chem. 2016 08; 62(8):1052-3.
-
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar; 35(3):689-99.
-
Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J Clin Lipidol. 2015 Mar-Apr; 9(2):201-9.
-
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Mar 20; 375(9719):998-1006.
-
Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. Atherosclerosis. 1997 Feb 28; 129(1):97-102.
-
Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. Arterioscler Thromb. 1993 Jul; 13(7):1076-81.